131 related articles for article (PubMed ID: 23115626)
1. Structure and activity analysis of Inauhzin analogs as novel antitumor compounds that induce p53 and inhibit cell growth.
Zhang Q; Ding D; Zeng SX; Ye QZ; Lu H
PLoS One; 2012; 7(10):e46294. PubMed ID: 23115626
[TBL] [Abstract][Full Text] [Related]
2. Nanoparticle encapsulation of non-genotoxic p53 activator Inauhzin-C for improved therapeutic efficacy.
Bhattarai N; Wang J; Nguyen D; Yang X; Helmers L; Paruch J; Li L; Zhang Y; Meng K; Wang A; Jayawickramarajah J; Wang B; Zeng S; Lu H
Theranostics; 2021; 11(14):7005-7017. PubMed ID: 34093867
[TBL] [Abstract][Full Text] [Related]
3. Global effect of inauhzin on human p53-responsive transcriptome.
Liao JM; Zeng SX; Zhou X; Lu H
PLoS One; 2012; 7(12):e52172. PubMed ID: 23284922
[TBL] [Abstract][Full Text] [Related]
4. A small molecule Inauhzin inhibits SIRT1 activity and suppresses tumour growth through activation of p53.
Zhang Q; Zeng SX; Zhang Y; Zhang Y; Ding D; Ye Q; Meroueh SO; Lu H
EMBO Mol Med; 2012 Apr; 4(4):298-312. PubMed ID: 22331558
[TBL] [Abstract][Full Text] [Related]
5. Inauhzin sensitizes p53-dependent cytotoxicity and tumor suppression of chemotherapeutic agents.
Zhang Y; Zhang Q; Zeng SX; Hao Q; Lu H
Neoplasia; 2013 May; 15(5):523-34. PubMed ID: 23633924
[TBL] [Abstract][Full Text] [Related]
6. Inauhzin(c) inactivates c-Myc independently of p53.
Jung JH; Liao JM; Zhang Q; Zeng S; Nguyen D; Hao Q; Zhou X; Cao B; Kim SH; Lu H
Cancer Biol Ther; 2015; 16(3):412-9. PubMed ID: 25692307
[TBL] [Abstract][Full Text] [Related]
7. The role of IMP dehydrogenase 2 in Inauhzin-induced ribosomal stress.
Zhang Q; Zhou X; Wu R; Mosley A; Zeng SX; Xing Z; Lu H
Elife; 2014 Oct; 3():. PubMed ID: 25347121
[TBL] [Abstract][Full Text] [Related]
8. Inauhzin and Nutlin3 synergistically activate p53 and suppress tumor growth.
Zhang Y; Zhang Q; Zeng SX; Zhang Y; Mayo LD; Lu H
Cancer Biol Ther; 2012 Aug; 13(10):915-24. PubMed ID: 22785205
[TBL] [Abstract][Full Text] [Related]
9. Calcium-oxidative stress signaling axis and casein kinase 1α mediate eryptosis and hemolysis elicited by novel p53 agonist inauhzin.
Alfhili MA; Alsalmi E; Aljedai A; Alsughayyir J; Abudawood M; Basudan AM
J Chemother; 2022 Jul; 34(4):247-257. PubMed ID: 34410893
[TBL] [Abstract][Full Text] [Related]
10. Determination of Maximum Tolerated Dose and Toxicity of Inauhzin in Mice.
Zhang Q; Zeng SX; Lu H
Toxicol Rep; 2015; 2():546-554. PubMed ID: 26167454
[TBL] [Abstract][Full Text] [Related]
11. TFIIS.h, a new target of p53, regulates transcription efficiency of pro-apoptotic bax gene.
Liao JM; Cao B; Deng J; Zhou X; Strong M; Zeng S; Xiong J; Flemington E; Lu H
Sci Rep; 2016 Mar; 6():23542. PubMed ID: 27005522
[TBL] [Abstract][Full Text] [Related]
12. Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction.
Ding K; Lu Y; Nikolovska-Coleska Z; Wang G; Qiu S; Shangary S; Gao W; Qin D; Stuckey J; Krajewski K; Roller PP; Wang S
J Med Chem; 2006 Jun; 49(12):3432-5. PubMed ID: 16759082
[TBL] [Abstract][Full Text] [Related]
13. MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53.
Canner JA; Sobo M; Ball S; Hutzen B; DeAngelis S; Willis W; Studebaker AW; Ding K; Wang S; Yang D; Lin J
Br J Cancer; 2009 Sep; 101(5):774-81. PubMed ID: 19707204
[TBL] [Abstract][Full Text] [Related]
14. Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction.
Yu S; Qin D; Shangary S; Chen J; Wang G; Ding K; McEachern D; Qiu S; Nikolovska-Coleska Z; Miller R; Kang S; Yang D; Wang S
J Med Chem; 2009 Dec; 52(24):7970-3. PubMed ID: 19928922
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and Evaluation of 2-Naphthaleno trans-Stilbenes and Cyanostilbenes as Anticancer Agents.
Madadi NR; Penthala NR; Ketkar A; Eoff RL; Trujullo-Alonso V; Guzman ML; Crooks PA
Anticancer Agents Med Chem; 2018; 18(4):556-564. PubMed ID: 28403783
[TBL] [Abstract][Full Text] [Related]
16. Hitting on the move: Targeting intrinsically disordered protein states of the MDM2-p53 interaction.
Neochoritis CG; Atmaj J; Twarda-Clapa A; Surmiak E; Skalniak L; Köhler LM; Muszak D; Kurpiewska K; Kalinowska-Tłuścik J; Beck B; Holak TA; Dömling A
Eur J Med Chem; 2019 Nov; 182():111588. PubMed ID: 31421630
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and Optimization of New 3,6-Disubstitutedindole Derivatives and Their Evaluation as Anticancer Agents Targeting the MDM2/MDMx Complex.
Rezk MS; Abdel-Halim M; Keeton A; Franklin D; Bauer M; Boeckler FM; Engel M; Hartmann RW; Zhang Y; Piazza GA; Abadi AH
Chem Pharm Bull (Tokyo); 2016; 64(1):34-41. PubMed ID: 26726742
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of novel antitumor spirotetrahydrothiopyran-oxindole derivatives as potent p53-MDM2 inhibitors.
Ji C; Wang S; Chen S; He S; Jiang Y; Miao Z; Li J; Sheng C
Bioorg Med Chem; 2017 Oct; 25(20):5268-5277. PubMed ID: 28797774
[TBL] [Abstract][Full Text] [Related]
19. Identification and structure-activity relationship studies of 3-methylene-2-norbornanone as potent anti-proliferative agents presumably working through p53 mediated apoptosis.
Reddy NL; Hill J; Ye L; Fernandes PB; Stout DM
Bioorg Med Chem Lett; 2004 Nov; 14(22):5645-9. PubMed ID: 15482940
[TBL] [Abstract][Full Text] [Related]
20. Trisubstituted and tetrasubstituted pyrazolines as a novel class of cell-growth inhibitors in tumor cells with wild type p53.
Abdel-Halim M; Keeton AB; Gurpinar E; Gary BD; Vogel SM; Engel M; Piazza GA; Boeckler FM; Hartmann RW; Abadi AH
Bioorg Med Chem; 2013 Dec; 21(23):7343-56. PubMed ID: 24139845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
